Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab.

ABSTRACT:

Background

Glioblastoma (GBM) is an aggressive and highly vascular tumor with median survival below 2 years. Despite advances in surgery, radiotherapy, and chemotherapy, survival has improved modestly. To combat glioma vascular proliferation, anti-angiogenic agents targeting vascular endothelial growth factor (VEGF) were introduced. Preclinically these agents were effective, yet they did not improve overall survival in phase III trials. We tested the hypothesis that ganciclovir (GCV)-mediated killing of proliferating endothelial cells expressing herpes simplex virus type 1 thymidine kinase (HSV1-TK) would have direct antitumor effects, and whether vessel ablation would affect the antitumor activity of anti-VEGF antibodies and radiotherapy.

Methods

Proliferating endothelial c

SUBMITTER: Yadav VN 

PROVIDER: S-EPMC6140787 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature